We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Quantification of epidermal growth factor receptor ( EGFR) mutation may be a predictor of EGFR-tyrosine kinase inhibitor treatment response.
- Authors
Park, Ha Young; Oh, Hyung Joo; Kim, Ki‐Hyun; Kim, Tae‐Ok; Park, Cheol‐Kyu; Shin, Hong‐Jun; Lim, Jung‐Hwan; Kwon, Yong‐Soo; Oh, In‐Jae; Kim, Yu‐Il; Lim, Sung‐Chul; Kim, Young‐Chul; Choi, Yoo‐Duk
- Abstract
Background Epidermal growth factor receptor ( EGFR) gene mutation is a reliable predictive factor for response to EGFR-tyrosine kinase inhibitors ( TKIs). The quantified EGFR value may also predict response and survival within an EGFR mutated group. Methods We conducted a retrospective study of 836 lung cancer patients. The patient sample was divided into two groups based on the mean delta cycle threshold (∆ Ct) value. EGFR mutation tests using peptide nucleic acid ( PNA)-mediated clamping polymerase chain reaction ( PCR) were performed. The efficiency of PCR clamping was determined by measuring the Ct value and EGFR quantification was determined by the corrected ∆ Ct value. Results EGFR mutation positivity was 30.1% and there were 235 single activating mutations. In this mutation group, the higher corrected ∆ Ct value (≥ mean value) group showed better objective response (70.9% vs. 54.9%, P = 0.022) and clinical benefit rates (86.4% vs. 68.3%, P = 0.003) than the lower group. In addition, corrected ∆ Ct values were significantly and inversely correlated with disease response ( r = −0.184, P = 0.017). In multivariate analysis, both female gender ( P = 0.014) and higher corrected Δ Ct value ( P = 0.012) were independent predictive factors for better clinical benefit rate. The higher corrected Δ Ct value group had a tendency for longer progression-free survival than the lower group ( P = 0.050). Conclusion The corrected ∆ Ct value, which refers to EGFR quantification by PNA-mediated PCR clamping, can predict better clinical response to EGFR- TKI therapy. However, further study is warranted to determine its value as a biomarker to reflect survival.
- Subjects
CANCER patients; COMPARATIVE studies; EPIDERMAL growth factor; LUNG tumors; MULTIVARIATE analysis; GENETIC mutation; POLYMERASE chain reaction; SURVIVAL; PROTEIN-tyrosine kinase inhibitors; RETROSPECTIVE studies; DISEASE progression; DESCRIPTIVE statistics
- Publication
Thoracic Cancer, 2016, Vol 7, Issue 6, p639
- ISSN
1759-7706
- Publication type
Article
- DOI
10.1111/1759-7714.12378